|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
2
|
|
pubmed:dateCreated |
2009-4-15
|
|
pubmed:abstractText |
The aim of this study was to estimate the cost-effectiveness of rituximab in patients not responding adequately to the first tumor necrosis factor (TNF) inhibitor using a model constructed to predict resource consumption and health outcomes in a population-based registry of biological treatments in Southern Sweden (SSATG).
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Apr
|
|
pubmed:issn |
1471-6348
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
25
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
181-9
|
|
pubmed:dateRevised |
2010-11-18
|
|
pubmed:meshHeading |
pubmed-meshheading:19331709-Antibodies, Monoclonal,
pubmed-meshheading:19331709-Antibodies, Monoclonal, Murine-Derived,
pubmed-meshheading:19331709-Antirheumatic Agents,
pubmed-meshheading:19331709-Arthritis, Rheumatoid,
pubmed-meshheading:19331709-Cost-Benefit Analysis,
pubmed-meshheading:19331709-Female,
pubmed-meshheading:19331709-Health Care Costs,
pubmed-meshheading:19331709-Humans,
pubmed-meshheading:19331709-Male,
pubmed-meshheading:19331709-Markov Chains,
pubmed-meshheading:19331709-Middle Aged,
pubmed-meshheading:19331709-Quality-Adjusted Life Years,
pubmed-meshheading:19331709-Registries,
pubmed-meshheading:19331709-Sweden,
pubmed-meshheading:19331709-Tumor Necrosis Factor-alpha
|
|
pubmed:year |
2009
|
|
pubmed:articleTitle |
Modeling the cost-effectiveness of treatment of rheumatoid arthritis with rituximab using registry data from Southern Sweden.
|
|
pubmed:affiliation |
i3/innovus, Klarabergsviadukten 90D, SE-111 64 Stockholm, Sweden. Peter.Lindgren@3innovus.com
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
